Fig. 12From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsAflibercept versus ranibizumab. Serious systemic adverse events comparing aflibercept with ranibizumab at 1 year. M-H, Mantel–Haenszel statisticsBack to article page